Pancreatic cancer and sarcopenia: a narrative review of the current status.
Mariko TsukagoshiKenichiro ArakiKen ShirabePublished in: International journal of clinical oncology (2024)
Pancreatic cancer is still a difficult disease to treat, despite recent advances in surgical techniques and chemotherapeutic drugs. Its incidence continues to rise, as does the number of older patients. Sarcopenia is defined as a progressive and generalized loss of skeletal muscle mass and strength. Sarcopenia is present in approximately 40% in patients with pancreatic cancer. Sarcopenia is primarily diagnosed through imaging, and progress is being made in the development of automated methods and artificial intelligence, as well as biomarker research. Sarcopenia has been linked to a poor prognosis in pancreatic cancer patients. However, some studies suggest that sarcopenia is not always associated with a poor prognosis, depending on the resectability of pancreatic cancer and the nature of treatment, such as surgery or chemotherapy. Recent meta-analyses have found that sarcopenia is not linked to postoperative complications. It is still debated whether there is a link between sarcopenia and drug toxicity during chemotherapy. The relationship between sarcopenia and immunity has been investigated, but the mechanism is still unknown.
Keyphrases
- poor prognosis
- skeletal muscle
- community dwelling
- artificial intelligence
- long non coding rna
- machine learning
- deep learning
- multiple sclerosis
- oxidative stress
- emergency department
- risk factors
- big data
- acute coronary syndrome
- radiation therapy
- atrial fibrillation
- photodynamic therapy
- coronary artery bypass
- percutaneous coronary intervention
- smoking cessation
- adverse drug
- fluorescence imaging
- electronic health record
- atomic force microscopy